

Steve Sisolak  
Governor



Richard Whitley, MS  
Director

**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
DIVISION OF PUBLIC AND BEHAVIORAL HEALTH  
*Helping people. It's who we are and what we do.*



Lisa Sherych  
Administrator

Ihsan Azzam,  
Ph.D., M.D.  
Chief Medical Officer

## Technical Bulletin

**Date:** April 5, 2022

**Topic:** BioPlex 2200 Syphilis Total & RPR Test Kit Recall

**Contact:** Elizabeth Kessler, MPH, STD Program Manager, Nevada Division of Public and Behavioral Health, Office of Public Health Investigations and Epidemiology

**To:** Health Care Providers, Medical Facilities, and Correctional Facilities

---

### Situation:

On February 8, 2022, BioRad issued a voluntary recall for the rapid plasma reagin (RPR) portion of the BioPlex 2200 Syphilis Total & RPR Test Kit due to current concerns related to COVID-19 vaccine interference and false reactive RPR results, as well as intermittent manufacturing challenges to produce the RPR reagents that consistently meet stability specifications. The U.S. Food and Drug Administration (FDA) classified this as a Class 2 Device Recall on March 16, 2022. BioRad Laboratories, Inc. has disabled the RPR portion of the Syphilis Total and RPR panels until further notice. Customers are instructed to:

1. Dispose of the reagents according to local waste management procedures.
2. If they have further distributed or transferred the product to other customers, or labs from their site, notify those customers of this field action.
3. Complete a customer response form and email or fax it to local Bio-Rad Technical Support.  
([techsupport.ussd@bio-rad.com](mailto:techsupport.ussd@bio-rad.com) or 1-888-228-0688)

Individuals who need syphilis testing should continue to get tested and receive the full testing algorithm. Testing locations can be found at Nevada 2-1-1: <https://www.nevada211.org/std-syphilis-testing/>

### Resources:

We encourage you to review this recall notice in detail:

[https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=192210&ACSTrackingID=USCDC\\_2146-DM78416&ACSTrackingLabel=Lab%20Alert%3A%20FDA%20Recalls%20BioPlex%202200%20Syphilis%20Total%20%26%20RPR%20Test%20Kit&deliveryName=USCDC\\_2146-DM78416](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=192210&ACSTrackingID=USCDC_2146-DM78416&ACSTrackingLabel=Lab%20Alert%3A%20FDA%20Recalls%20BioPlex%202200%20Syphilis%20Total%20%26%20RPR%20Test%20Kit&deliveryName=USCDC_2146-DM78416)

### Questions:

For updated guidance, please review the DPBH Technical Bulletin [website](#). For questions about this technical bulletin, contact Elizabeth Kessler at (775) 447-4494 or [ekessler@health.nv.gov](mailto:ekessler@health.nv.gov) or the Laboratory Outreach Communication System (LOCS) at [LOCS@CDC.gov](mailto:LOCS@CDC.gov).

Handwritten signature of Lisa Sherych in blue ink.

Lisa Sherych, Administrator  
Division of Public and Behavioral Health

Handwritten signature of Ihsan Azzam in blue ink.

Ihsan Azzam, Ph.D., M.D.  
Chief Medical Officer